Lung Cancer

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 337509 Experts worldwide ranked by ideXlab platform

Li Rita Zhang - One of the best experts on this subject based on the ideXlab platform.

  • cannabis smoking and Lung Cancer risk pooled analysis in the international Lung Cancer consortium
    International Journal of Cancer, 2015
    Co-Authors: Li Rita Zhang, Hal Morgenstern, Sander Greenland, Shen Chih Chang, Philip Lazarus, Dawn M Teare, Penella J Woll, Irene Orlow, Brian Cox, Yonathan Brhane
    Abstract:

    To investigate the association between cannabis smoking and Lung Cancer risk, data on 2,159 Lung Cancer cases and 2,985 controls were pooled from 6 case-control studies in the US, Canada, UK, and New Zealand within the International Lung Cancer Consortium. Study-specific associations between cannabis smoking and Lung Cancer were estimated using unconditional logistic regression adjusting for sociodemographic factors, tobacco smoking status and pack-years; odds-ratio estimates were pooled using random effects models. Subgroup analyses were done for sex, histology and tobacco smoking status. The shapes of dose-response associations were examined using restricted cubic spline regression. The overall pooled OR for habitual versus nonhabitual or never users was 0.96 (95% CI: 0.66-1.38). Compared to nonhabitual or never users, the summary OR was 0.88 (95%CI: 0.63-1.24) for individuals who smoked 1 or more joint-equivalents of cannabis per day and 0.94 (95%CI: 0.67-1.32) for those consumed at least 10 joint-years. For adenocarcinoma cases the ORs were 1.73 (95%CI: 0.75-4.00) and 1.74 (95%CI: 0.85-3.55), respectively. However, no association was found for the squamous cell carcinoma based on small numbers. Weak associations between cannabis smoking and Lung Cancer were observed in never tobacco smokers. Spline modeling indicated a weak positive monotonic association between cumulative cannabis use and Lung Cancer, but precision was low at high exposure levels. Results from our pooled analyses provide little evidence for an increased risk of Lung Cancer among habitual or long-term cannabis smokers, although the possibility of potential adverse effect for heavy consumption cannot be excluded.

  • abstract 3633 cannabis smoking and Lung Cancer risk pooled analysis in the international Lung Cancer consortium
    Cancer Research, 2013
    Co-Authors: Li Rita Zhang, Hal Morgenstern, Shen Chih Chang, Philip Lazarus, Dawn M Teare, Penella J Woll, Irene Orlow, Brian Cox, Zuofeng Zhang, Geoffrey Liu
    Abstract:

    Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background Lung Cancer remains the leading cause of Cancer death worldwide, with tobacco smoking established as the main risk factor. Cannabis smoke contains similar carcinogens as tobacco smoke including the polycyclic aromatic hydrocarbons; animal studies and human case series and histopathologic studies have suggested its potential carcinogenic effect in Lungs. However, epidemiologic evidence is limited and conflicting. The present study aimed to examine the role of cannabis smoking in Lung Cancer risk using a pooled analysis in the International Lung Cancer Consortium (ILCCO). Methods Cannabis smoking and putative Lung Cancer risk factor data on 2131 Lung Cancer cases and 3075 controls were harmonized and pooled from six case-control studies in US, Canada, UK and New Zealand within the ILCCO. To standardize the definition and to distinguish occasional/non-users from habitual users, cumulative consumption of 1 joint-year (1 joint-equivalent per day for 1 year) or more was used to define habitual vs. non-users. The association between cannabis smoking (habitual vs. non-users, joint-equivalent per day, duration, and total joint-years) and the risk of Lung Cancer was assessed by odds ratios (OR) and 95% confidence intervals (CI) obtained from unconditional logistic regression in each study, while adjusting for age, sex, sociodemographic factors and tobacco packyears. Pooled risk estimates were calculated using random effect models. To minimize confounding by tobacco smoking, we also conducted analyses restricted to 367 case and 1400 control never tobacco smokers. Results The summary OR from the six studies for habitual vs. non-users was 1.15 (95% CI: 0.73-1.82, p for heterogeneity: 0.05). Compared to non-users, the summary OR was 1.28 (95%CI: 0.62-2.63) for individuals who smoked cannabis for 20 years or more and 1.53 (95%CI: 0.57-4.09) for those with 10 joint-years or more cumulative consumption. A lack of significant association between cannabis smoking and Lung Cancer was also observed in the never tobacco smokers: compared to non-users, the OR was 0.99 (95% CI: 0.49-2.00) for habitual users and 2.13 (95%CI: 0.67-6.78) for those who used 20 years or more. Conclusion Our pooled results showed no significant association between the intensity, duration, or cumulative consumption of cannabis smoke and the risk of Lung Cancer overall or in never smokers. Cannabis use is under international control and its legal status varies, so reporting bias is of concern. However, since the reported prevalence in our data is comparable to nation-specific survey results and not differential between cases and controls, it is unlikely to fully explain the lack of significant association. Our results cannot preclude the possibility that cannabis may exhibit an association with Lung Cancer risk at extremely high dosage. We will also present data after applying restricted cubic splines to explore non-linear relationships. Citation Format: Li Rita Zhang, Zuo-Feng Zhang, Hal Morgenstern, Shen-Chih Chang, Philip Lazarus, M. Dawn Teare, Penella J. Woll, Irene Orlow, Brian Cox, Geoffrey Liu, Rayjean J. Hung. Cannabis smoking and Lung Cancer risk: pooled analysis in the International Lung Cancer Consortium. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3633. doi:10.1158/1538-7445.AM2013-3633

Shen Chih Chang - One of the best experts on this subject based on the ideXlab platform.

  • cannabis smoking and Lung Cancer risk pooled analysis in the international Lung Cancer consortium
    International Journal of Cancer, 2015
    Co-Authors: Li Rita Zhang, Hal Morgenstern, Sander Greenland, Shen Chih Chang, Philip Lazarus, Dawn M Teare, Penella J Woll, Irene Orlow, Brian Cox, Yonathan Brhane
    Abstract:

    To investigate the association between cannabis smoking and Lung Cancer risk, data on 2,159 Lung Cancer cases and 2,985 controls were pooled from 6 case-control studies in the US, Canada, UK, and New Zealand within the International Lung Cancer Consortium. Study-specific associations between cannabis smoking and Lung Cancer were estimated using unconditional logistic regression adjusting for sociodemographic factors, tobacco smoking status and pack-years; odds-ratio estimates were pooled using random effects models. Subgroup analyses were done for sex, histology and tobacco smoking status. The shapes of dose-response associations were examined using restricted cubic spline regression. The overall pooled OR for habitual versus nonhabitual or never users was 0.96 (95% CI: 0.66-1.38). Compared to nonhabitual or never users, the summary OR was 0.88 (95%CI: 0.63-1.24) for individuals who smoked 1 or more joint-equivalents of cannabis per day and 0.94 (95%CI: 0.67-1.32) for those consumed at least 10 joint-years. For adenocarcinoma cases the ORs were 1.73 (95%CI: 0.75-4.00) and 1.74 (95%CI: 0.85-3.55), respectively. However, no association was found for the squamous cell carcinoma based on small numbers. Weak associations between cannabis smoking and Lung Cancer were observed in never tobacco smokers. Spline modeling indicated a weak positive monotonic association between cumulative cannabis use and Lung Cancer, but precision was low at high exposure levels. Results from our pooled analyses provide little evidence for an increased risk of Lung Cancer among habitual or long-term cannabis smokers, although the possibility of potential adverse effect for heavy consumption cannot be excluded.

  • exposure to secondhand tobacco smoke and Lung Cancer by histological type a pooled analysis of the international Lung Cancer consortium ilcco
    International Journal of Cancer, 2014
    Co-Authors: Claire H Kim, Shen Chih Chang, Yuan Chin Amy Lee, Rayjean J Hung, Sheila R Mcnallan, Michele L Cote, Weiyen Lim, Jin Hee Kim, Donatella Ugolini
    Abstract:

    While the association between exposure to secondhand smoke and Lung Cancer risk is well established, few studies with sufficient power have examined the association by histological type. In this study, we evaluated the secondhand smoke-Lung Cancer relationship by histological type based on pooled data from 18 case-control studies in the International Lung Cancer Consortium (ILCCO), including 2,504 cases and 7,276 control who were never smokers and 10,184 cases and 7,176 controls who were ever smokers. We used multivariable logistic regression, adjusting for age, sex, race/ethnicity, smoking status, pack-years of smoking, and study. Among never smokers, the odds ratios (OR) comparing those ever exposed to secondhand smoke with those never exposed were 1.31 (95% CI: 1.17-1.45) for all histological types combined, 1.26 (95% CI: 1.10-1.44) for adenocarcinoma, 1.41 (95% CI: 0.99-1.99) for squamous cell carcinoma, 1.48 (95% CI: 0.89-2.45) for large cell Lung Cancer, and 3.09 (95% CI: 1.62-5.89) for small cell Lung Cancer. The estimated association with secondhand smoke exposure was greater for small cell Lung Cancer than for nonsmall cell Lung Cancers (OR=2.11, 95% CI: 1.11-4.04). This analysis is the largest to date investigating the relation between exposure to secondhand smoke and Lung Cancer. Our study provides more precise estimates of the impact of secondhand smoke on the major histological types of Lung Cancer, indicates the association with secondhand smoke is stronger for small cell Lung Cancer than for the other histological types, and suggests the importance of intervention against exposure to secondhand smoke in Lung Cancer prevention.

  • abstract 3633 cannabis smoking and Lung Cancer risk pooled analysis in the international Lung Cancer consortium
    Cancer Research, 2013
    Co-Authors: Li Rita Zhang, Hal Morgenstern, Shen Chih Chang, Philip Lazarus, Dawn M Teare, Penella J Woll, Irene Orlow, Brian Cox, Zuofeng Zhang, Geoffrey Liu
    Abstract:

    Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background Lung Cancer remains the leading cause of Cancer death worldwide, with tobacco smoking established as the main risk factor. Cannabis smoke contains similar carcinogens as tobacco smoke including the polycyclic aromatic hydrocarbons; animal studies and human case series and histopathologic studies have suggested its potential carcinogenic effect in Lungs. However, epidemiologic evidence is limited and conflicting. The present study aimed to examine the role of cannabis smoking in Lung Cancer risk using a pooled analysis in the International Lung Cancer Consortium (ILCCO). Methods Cannabis smoking and putative Lung Cancer risk factor data on 2131 Lung Cancer cases and 3075 controls were harmonized and pooled from six case-control studies in US, Canada, UK and New Zealand within the ILCCO. To standardize the definition and to distinguish occasional/non-users from habitual users, cumulative consumption of 1 joint-year (1 joint-equivalent per day for 1 year) or more was used to define habitual vs. non-users. The association between cannabis smoking (habitual vs. non-users, joint-equivalent per day, duration, and total joint-years) and the risk of Lung Cancer was assessed by odds ratios (OR) and 95% confidence intervals (CI) obtained from unconditional logistic regression in each study, while adjusting for age, sex, sociodemographic factors and tobacco packyears. Pooled risk estimates were calculated using random effect models. To minimize confounding by tobacco smoking, we also conducted analyses restricted to 367 case and 1400 control never tobacco smokers. Results The summary OR from the six studies for habitual vs. non-users was 1.15 (95% CI: 0.73-1.82, p for heterogeneity: 0.05). Compared to non-users, the summary OR was 1.28 (95%CI: 0.62-2.63) for individuals who smoked cannabis for 20 years or more and 1.53 (95%CI: 0.57-4.09) for those with 10 joint-years or more cumulative consumption. A lack of significant association between cannabis smoking and Lung Cancer was also observed in the never tobacco smokers: compared to non-users, the OR was 0.99 (95% CI: 0.49-2.00) for habitual users and 2.13 (95%CI: 0.67-6.78) for those who used 20 years or more. Conclusion Our pooled results showed no significant association between the intensity, duration, or cumulative consumption of cannabis smoke and the risk of Lung Cancer overall or in never smokers. Cannabis use is under international control and its legal status varies, so reporting bias is of concern. However, since the reported prevalence in our data is comparable to nation-specific survey results and not differential between cases and controls, it is unlikely to fully explain the lack of significant association. Our results cannot preclude the possibility that cannabis may exhibit an association with Lung Cancer risk at extremely high dosage. We will also present data after applying restricted cubic splines to explore non-linear relationships. Citation Format: Li Rita Zhang, Zuo-Feng Zhang, Hal Morgenstern, Shen-Chih Chang, Philip Lazarus, M. Dawn Teare, Penella J. Woll, Irene Orlow, Brian Cox, Geoffrey Liu, Rayjean J. Hung. Cannabis smoking and Lung Cancer risk: pooled analysis in the International Lung Cancer Consortium. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3633. doi:10.1158/1538-7445.AM2013-3633

Richard A Matthay - One of the best experts on this subject based on the ideXlab platform.

  • Lung Cancer epidemiology etiology and prevention
    Clinics in Chest Medicine, 2011
    Co-Authors: Charles Dela S Cruz, Lynn T Tanoue, Richard A Matthay
    Abstract:

    A vast majority of Lung Cancer deaths are attributable to cigarette smoking, and curbing the rates of cigarette smoking is imperative. Understanding the epidemiology and causal factors of Lung Cancer can provide additional foundation for disease prevention. The role of tobacco as an etiologic factor in Lung Cancer has been convincingly established. Likewise, ionizing radiation and certain occupational exposures have been recognized as carcinogenic. At present, the 5-year survival rate for Lung Cancer is only 15.6%. This is in stark contrast to the 5-year survival rates for the other leading causes of Cancer death in the United States, including Cancers of the colon (66%), skin (melanoma 93%), breast (90%), and prostate (100%).1 The absolute number of Lung Cancer cases continues to be alarming, with the continued rise of Lung Cancer in women a particularly disturbing feature. The challenge in the future will be to modify the impact of these identified external sources of risk while continuing to expand knowledge of the genetic and molecular basis of carcinogenesis. Early diagnosis of Lung Cancer is imperative because the 5-year survival rate for treated stage I Lung Cancer is substantially better than for stages II to IV. The issue of benefit related to Lung Cancer screening is being actively revisited. The American Cancer Society does not currently recommend routine screening for Lung Cancer. The American College of Chest Physicians guidelines for Lung Cancer screening only recommend it for persons who are part of a clinical trial. Prior trials from the 1970s and 1980s demonstrating no reduction in Cancer mortality despite screening by chest radiograph effectively eliminated such testing. Petty276 points out that groups at high risk, specifically heavy smokers with spirometric and clinical evidence of airflow obstruction, can be easily identified. Many clinicians think that screening with chest radiography and sputum cytology in such groups might be justifiable. Recent National Lung Screening Trial study shows that using low-dose CT scans to screen for Lung Cancer resulted in a 20% reduction in deaths from the disease.277 As promising as the National Lung Screening Trial results are, official guidelines on CT scan for Lung Cancer screening are not available pending careful evaluation of the new data to determine who should or should not consider undergo screen for early Lung Cancer detection. It is hoped that ongoing trials evaluating chest radiography, chest CT scanning, and sputum cytology will clarify this important controversial issue. At present, with approximately a quarter of the American population still smoking cigarettes, continued efforts must be directed at smoking cessation and at preventing persons from becoming addicted to smoking. Although work in the field of Lung Cancer treatment continues to be and remains important, the dismal survival rate associated with this disease demands that the medical profession contribute to efforts aimed at limiting its primary cause. If tobacco smoking could be eliminated, or at least severely curtailed, and if some of the other known exposure risks of Lung Cancer are addressed, only then may Lung Cancer be able to be returned to its designation by Adler16 at the turn of the twentieth century as “among the rarest forms of disease.”

  • Lung Cancer epidemiology etiology and prevention
    Clinics in Chest Medicine, 2011
    Co-Authors: Charles Dela S Cruz, Lynn T Tanoue, Richard A Matthay
    Abstract:

    Lung Cancer is the leading cause of Cancer death in the United States and around the world. A vast majority of Lung Cancer deaths are attributable to cigarette smoking, and curbing the rates of cigarette smoking is imperative. Understanding the epidemiology and causal factors of Lung Cancer can provide additional foundation for disease prevention. This article focuses on modifiable risk factors, including tobacco smoking, occupational carcinogens, diet, and ionizing radiation. It also discusses briefly the molecular and genetic aspects of Lung carcinogenesis.

  • epidemiology etiology and prevention of Lung Cancer
    Clinics in Chest Medicine, 2002
    Co-Authors: Kathryn Smith Bilello, Susan Murin, Richard A Matthay
    Abstract:

    Over the past century, Lung Cancer has gone from an obscure disease to the leading cause of Cancer death worldwide. Initially an epidemic disease among men in industrialized nations, Lung Cancer now has become the leading Cancer killer in both sexes in the United States and an increasingly common disease of both sexes in developing countries. Lung Cancer incidence largely mirrors smoking prevalence, with a latency period of several decades. Other important risk factors for the development of Lung Cancer include environmental exposure to tobacco smoke, radon, occupational carcinogens, and pre-existing nonmalignant Lung disease. Studies in molecular biology have elucidated the role that genetic factors play in modifying an individual's risk for Lung Cancer. Although chemopreventive agents may be developed to prevent Lung Cancer, prevention of smoking initiation and promotion of smoking cessation are currently the best weapons to fight Lung Cancer. No other malignancy has been shown to have such a strong epidemiologic relation between a preventable behavior and incidence of disease. Despite this knowledge, more than 20% of all Americans smoke, and tobacco use is exploding in developing countries. Based on current and projected smoking patterns, it is anticipated that Lung Cancer will remain the leading cause of Cancer death in the world for decades to come.

Geoffrey Liu - One of the best experts on this subject based on the ideXlab platform.

  • abstract 3633 cannabis smoking and Lung Cancer risk pooled analysis in the international Lung Cancer consortium
    Cancer Research, 2013
    Co-Authors: Li Rita Zhang, Hal Morgenstern, Shen Chih Chang, Philip Lazarus, Dawn M Teare, Penella J Woll, Irene Orlow, Brian Cox, Zuofeng Zhang, Geoffrey Liu
    Abstract:

    Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background Lung Cancer remains the leading cause of Cancer death worldwide, with tobacco smoking established as the main risk factor. Cannabis smoke contains similar carcinogens as tobacco smoke including the polycyclic aromatic hydrocarbons; animal studies and human case series and histopathologic studies have suggested its potential carcinogenic effect in Lungs. However, epidemiologic evidence is limited and conflicting. The present study aimed to examine the role of cannabis smoking in Lung Cancer risk using a pooled analysis in the International Lung Cancer Consortium (ILCCO). Methods Cannabis smoking and putative Lung Cancer risk factor data on 2131 Lung Cancer cases and 3075 controls were harmonized and pooled from six case-control studies in US, Canada, UK and New Zealand within the ILCCO. To standardize the definition and to distinguish occasional/non-users from habitual users, cumulative consumption of 1 joint-year (1 joint-equivalent per day for 1 year) or more was used to define habitual vs. non-users. The association between cannabis smoking (habitual vs. non-users, joint-equivalent per day, duration, and total joint-years) and the risk of Lung Cancer was assessed by odds ratios (OR) and 95% confidence intervals (CI) obtained from unconditional logistic regression in each study, while adjusting for age, sex, sociodemographic factors and tobacco packyears. Pooled risk estimates were calculated using random effect models. To minimize confounding by tobacco smoking, we also conducted analyses restricted to 367 case and 1400 control never tobacco smokers. Results The summary OR from the six studies for habitual vs. non-users was 1.15 (95% CI: 0.73-1.82, p for heterogeneity: 0.05). Compared to non-users, the summary OR was 1.28 (95%CI: 0.62-2.63) for individuals who smoked cannabis for 20 years or more and 1.53 (95%CI: 0.57-4.09) for those with 10 joint-years or more cumulative consumption. A lack of significant association between cannabis smoking and Lung Cancer was also observed in the never tobacco smokers: compared to non-users, the OR was 0.99 (95% CI: 0.49-2.00) for habitual users and 2.13 (95%CI: 0.67-6.78) for those who used 20 years or more. Conclusion Our pooled results showed no significant association between the intensity, duration, or cumulative consumption of cannabis smoke and the risk of Lung Cancer overall or in never smokers. Cannabis use is under international control and its legal status varies, so reporting bias is of concern. However, since the reported prevalence in our data is comparable to nation-specific survey results and not differential between cases and controls, it is unlikely to fully explain the lack of significant association. Our results cannot preclude the possibility that cannabis may exhibit an association with Lung Cancer risk at extremely high dosage. We will also present data after applying restricted cubic splines to explore non-linear relationships. Citation Format: Li Rita Zhang, Zuo-Feng Zhang, Hal Morgenstern, Shen-Chih Chang, Philip Lazarus, M. Dawn Teare, Penella J. Woll, Irene Orlow, Brian Cox, Geoffrey Liu, Rayjean J. Hung. Cannabis smoking and Lung Cancer risk: pooled analysis in the International Lung Cancer Consortium. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3633. doi:10.1158/1538-7445.AM2013-3633

Hal Morgenstern - One of the best experts on this subject based on the ideXlab platform.

  • cannabis smoking and Lung Cancer risk pooled analysis in the international Lung Cancer consortium
    International Journal of Cancer, 2015
    Co-Authors: Li Rita Zhang, Hal Morgenstern, Sander Greenland, Shen Chih Chang, Philip Lazarus, Dawn M Teare, Penella J Woll, Irene Orlow, Brian Cox, Yonathan Brhane
    Abstract:

    To investigate the association between cannabis smoking and Lung Cancer risk, data on 2,159 Lung Cancer cases and 2,985 controls were pooled from 6 case-control studies in the US, Canada, UK, and New Zealand within the International Lung Cancer Consortium. Study-specific associations between cannabis smoking and Lung Cancer were estimated using unconditional logistic regression adjusting for sociodemographic factors, tobacco smoking status and pack-years; odds-ratio estimates were pooled using random effects models. Subgroup analyses were done for sex, histology and tobacco smoking status. The shapes of dose-response associations were examined using restricted cubic spline regression. The overall pooled OR for habitual versus nonhabitual or never users was 0.96 (95% CI: 0.66-1.38). Compared to nonhabitual or never users, the summary OR was 0.88 (95%CI: 0.63-1.24) for individuals who smoked 1 or more joint-equivalents of cannabis per day and 0.94 (95%CI: 0.67-1.32) for those consumed at least 10 joint-years. For adenocarcinoma cases the ORs were 1.73 (95%CI: 0.75-4.00) and 1.74 (95%CI: 0.85-3.55), respectively. However, no association was found for the squamous cell carcinoma based on small numbers. Weak associations between cannabis smoking and Lung Cancer were observed in never tobacco smokers. Spline modeling indicated a weak positive monotonic association between cumulative cannabis use and Lung Cancer, but precision was low at high exposure levels. Results from our pooled analyses provide little evidence for an increased risk of Lung Cancer among habitual or long-term cannabis smokers, although the possibility of potential adverse effect for heavy consumption cannot be excluded.

  • abstract 3633 cannabis smoking and Lung Cancer risk pooled analysis in the international Lung Cancer consortium
    Cancer Research, 2013
    Co-Authors: Li Rita Zhang, Hal Morgenstern, Shen Chih Chang, Philip Lazarus, Dawn M Teare, Penella J Woll, Irene Orlow, Brian Cox, Zuofeng Zhang, Geoffrey Liu
    Abstract:

    Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background Lung Cancer remains the leading cause of Cancer death worldwide, with tobacco smoking established as the main risk factor. Cannabis smoke contains similar carcinogens as tobacco smoke including the polycyclic aromatic hydrocarbons; animal studies and human case series and histopathologic studies have suggested its potential carcinogenic effect in Lungs. However, epidemiologic evidence is limited and conflicting. The present study aimed to examine the role of cannabis smoking in Lung Cancer risk using a pooled analysis in the International Lung Cancer Consortium (ILCCO). Methods Cannabis smoking and putative Lung Cancer risk factor data on 2131 Lung Cancer cases and 3075 controls were harmonized and pooled from six case-control studies in US, Canada, UK and New Zealand within the ILCCO. To standardize the definition and to distinguish occasional/non-users from habitual users, cumulative consumption of 1 joint-year (1 joint-equivalent per day for 1 year) or more was used to define habitual vs. non-users. The association between cannabis smoking (habitual vs. non-users, joint-equivalent per day, duration, and total joint-years) and the risk of Lung Cancer was assessed by odds ratios (OR) and 95% confidence intervals (CI) obtained from unconditional logistic regression in each study, while adjusting for age, sex, sociodemographic factors and tobacco packyears. Pooled risk estimates were calculated using random effect models. To minimize confounding by tobacco smoking, we also conducted analyses restricted to 367 case and 1400 control never tobacco smokers. Results The summary OR from the six studies for habitual vs. non-users was 1.15 (95% CI: 0.73-1.82, p for heterogeneity: 0.05). Compared to non-users, the summary OR was 1.28 (95%CI: 0.62-2.63) for individuals who smoked cannabis for 20 years or more and 1.53 (95%CI: 0.57-4.09) for those with 10 joint-years or more cumulative consumption. A lack of significant association between cannabis smoking and Lung Cancer was also observed in the never tobacco smokers: compared to non-users, the OR was 0.99 (95% CI: 0.49-2.00) for habitual users and 2.13 (95%CI: 0.67-6.78) for those who used 20 years or more. Conclusion Our pooled results showed no significant association between the intensity, duration, or cumulative consumption of cannabis smoke and the risk of Lung Cancer overall or in never smokers. Cannabis use is under international control and its legal status varies, so reporting bias is of concern. However, since the reported prevalence in our data is comparable to nation-specific survey results and not differential between cases and controls, it is unlikely to fully explain the lack of significant association. Our results cannot preclude the possibility that cannabis may exhibit an association with Lung Cancer risk at extremely high dosage. We will also present data after applying restricted cubic splines to explore non-linear relationships. Citation Format: Li Rita Zhang, Zuo-Feng Zhang, Hal Morgenstern, Shen-Chih Chang, Philip Lazarus, M. Dawn Teare, Penella J. Woll, Irene Orlow, Brian Cox, Geoffrey Liu, Rayjean J. Hung. Cannabis smoking and Lung Cancer risk: pooled analysis in the International Lung Cancer Consortium. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3633. doi:10.1158/1538-7445.AM2013-3633